(Q37378233)

20 August 2017

1 reference

title

The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer (English)

1 reference

20 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

Laura Boehnke Michaud

series ordinal

1

1 reference

20 August 2017

publication date

26 January 2009

1 reference

Journal of Oncology Pharmacy Practice

20 August 2017

published in

1 reference

20 August 2017

volume

15

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

95-106

1 reference

Chemotherapy: what progress in the last 5 years?

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Facts and controversies in systemic treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Molecular mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Epothilones: mechanism of action and biologic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

The chemistry and biology of epothilones--the wheel keeps turning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Novel agents that target tublin and related elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Management of toxicities associated with the administration of taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Management and preparedness for infusion and hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155208100095

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.49.560

Identifiers

DOI

10.1177/1078155208100095

1 reference

20 August 2017

1 reference